Exemestane vs. tamoxifen as adjuvant therapy for postmenopausal women with primary breast cancer who have received adjuvant tamoxifen for 2-3 years

Study Chairs
Dr. Hervé Bonnefoi - Genève, Switzerland
Prof. Alan Coates - Centennial Park, Australia

Lead Trial Coordinator
Holly Shaw

IBCSG Data Management Center/FSTRF
4033 Maple Road
Amherst, New York 14226 USA
Phone: +1 716 834 0900
Fax: +1 716 833 3990
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.


Date of Activation
May 1998

Date of Closure
August 31, 2001

Targeted Accrual
4400 patients

Final Accrual
4742 patients

International Breast
Cancer Study Group

Effingerstrasse 40
3008 Bern, Switzerland

Contact
Phone: +41 31 511 94 00
E-mail: ibcsgcc@ibcsg.org

Member Login